Founded in 2004, ERYTECH Pharma develops innovative cancer therapies that work by starving tumours. Its first product, which is in phase III development, provides a therapeutic solution to frail patients with acute leukaemia.
ERYTECH proprietary technology is based on encapsulation of therapeutic molecules into red blood cells.
The company has a production unit located in Lyons with “Pharmaceutical Establishment” status. It has signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
ERYTECH successfully raises €30 million for expanding its therapeutic indications in oncology and accelerating its clinical developments
ERYTECH announces the granting of a new patent in the field of asparaginase in the United States.
ERYTECH wins EuropaBio’s Most Innovative European Biotech SME Award 2014
ERYTECH reports positive Phase III results from its pivotal study with GRASPA® in Acute Lymphoblastic Leukemia.
FINANCE – ERYTECH Pharma attends German Equity Forum from November 24 to 26, 2014 in Frankfurt, Germany.
FINANCE – ERYTECH Pharma participates in Actionaria 2014 on November 21 & 22, 2014 in Paris, France.
FINANCE – ERYTECH Pharma takes part in Jefferies Global Healthcare Conference on November 19 & 20, 2014 in London, UK.
ERYTECH Pharma participates in Bio Europe 2014 from November 3 to 5 in Frankfurt, Germany.